Search company, investor...

Altair Therapeutics

Founded Year



Series A - II | Alive

Total Raised


Last Raised

$17M | 13 yrs ago

About Altair Therapeutics

Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.

Headquarters Location

12555 High Bluff Drive Suite 310

San Diego, California, 92130,

United States


Missing: Altair Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Altair Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Altair Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Altair Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Latest Altair Therapeutics News

Isis Spinoff Altair Therapeutics Shut Down, After Mid-Stage Asthma Study Fails

Feb 4, 2011

XconomySan Diego —  San Diego-based Altair Therapeutics, a spinoff from Isis Pharmaceuticals (NASDAQ: ISIS ), has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma, Xconomy has learned. Carlsbad, CA-based Isis told investors back in November on its quarterly conference call that Altair’s lead drug candidate, AIR645, failed to show enough evidence of benefit in patients. Since then, Isis re-acquired the assets of Altair, halted further clinical development of the drug, and dissolved the company, Isis spokeswoman Amy Blackley says. “We were disappointed,” Blackley says. “The drug was well tolerated and showed signs of activity in early studies, but not enough clinical activity to warrant further development.” The company was dissolved, as well, because AIR645 “was the only drug they had,” Blackley says. A number of big-name venture groups made a sizable bet on Altair back in November 2009 . The company raised $17 million at the time from Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners, Forward Ventures, and Isis. The company was led by Joel Martin, a former partner at Forward Ventures. Altair’s vision was to use antisense technology, which is supposed to specifically shut down activity of certain proteins, to silence the activity of two inflammatory molecules that play a role in asthma—IL-4 and IL-13. Altair hoped to tap into a potentially huge market of millions of asthmatic patients, with a drug that works via a novel biological mechanism. Terms of the asset sale aren’t being made public. Altair only had seven employees because it operated in a “virtual” model that leaned heavily on contractors, Martin says. The Altair employees have mostly gone on to find other jobs since the company wound down in December, he says. Personally, Martin says he’s trying to take some time off, but is already thinking about what he’ll do next. He might choose to run another biotech startup, he says, noting that he’s interested in a new idea for neurology drug development.

Altair Therapeutics Frequently Asked Questions (FAQ)

  • When was Altair Therapeutics founded?

    Altair Therapeutics was founded in 2007.

  • Where is Altair Therapeutics's headquarters?

    Altair Therapeutics's headquarters is located at 12555 High Bluff Drive, San Diego.

  • What is Altair Therapeutics's latest funding round?

    Altair Therapeutics's latest funding round is Series A - II.

  • How much did Altair Therapeutics raise?

    Altair Therapeutics raised a total of $17M.

  • Who are the investors of Altair Therapeutics?

    Investors of Altair Therapeutics include Ionis Pharmaceuticals, Forward Ventures, Domain Associates, AgeChem and Thomas McNerney & Partners.

  • Who are Altair Therapeutics's competitors?

    Competitors of Altair Therapeutics include Array Biopharma, Iconic Therapeutics, Threshold Pharmaceuticals, Dendreon, REGiMMUNE and 11 more.

Compare Altair Therapeutics to Competitors

Trellis Bioscience

Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.

SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.


Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

Athersys Logo

Athersys develops biotechnology-based therapeutics.

Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.